
|Videos|November 26, 2013
The Treatment of Hairy Cell Leukemia
Author(s)Jae Park, MD
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia.
Advertisement
Clinical Pearls
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia.
- Patients with hairy cell leukemia typically receive cladribine or pentostatin and experience a long remission
- Patients are able to respond again to cladribine or pentostatin following relapse
- There are limited options for those who have gone through many lines of therapy
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































